{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:27:24Z","timestamp":1793978844833,"version":"4.8.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Pregnancy is associated with altered pharmacokinetics for several drugs.<\/jats:p>\n                    <jats:p>The blood concentration of infliximab increases during pregnancy, whereas that of vedolizumab tends to decrease. As autoimmune disease activity during pregnancy can lead to adverse pregnancy outcomes, monitoring drug concentrations during pregnancy is important.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study reports a 32-year-old female patient with severe juvenile idiopathic arthritis and Crohn disease who was treated with dual biologic therapy throughout her pregnancy. The measurements were performed as part of routine care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The patient was treated with vedolizumab and infliximab during the course of her pregnancy. Both autoimmune diseases remained unaffected throughout pregnancy, and therapeutic drug concentrations were monitored to guide treatment. The patient had gestational diabetes and mild polyhydramnios. Ultimately, the pregnancy was complicated by preterm delivery at 33 weeks and 5 days of gestation, with a good birth weight of 2425 g at p85 without growth retardation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Therapeutic drug monitoring (TDM) supports optimal dosing and effective disease control, highlighting the importance of individual interpretations. All TDM-initiated dosing changes were based on expert opinions, owing to the lack of validated guidelines on dosing during pregnancy. However, preterm birth could not be avoided and may be influenced by underlying autoimmune diseases, gestational diabetes, and mild polyhydramnios. Multidisciplinary care is essential in pregnant women with autoimmune disorders. Prospective research focusing on drug concentrations, disease activity, and the risk of adverse pregnancy outcomes is needed to understand the safety and implications of dual biologic therapies during pregnancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001519","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:00:31Z","timestamp":1790175631000},"page":"713-716","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Use of Two Biologics During Pregnancy: Infliximab and Vedolizumab: A Case Study"],"prefix":"10.1097","volume":"48","author":[{"given":"Birgit","family":"Hoekstra","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianne G.","family":"Bouwknegt","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Mian","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands;"},{"name":"Department of Pediatrics, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Dijkstra","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha K.","family":"Leijsma","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00ebtte","family":"Groenewout","sequence":"additional","affiliation":[{"name":"Department of Gynaecology and Obstetrics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijn C.","family":"Visschedijk","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"R1-20261106","first-page":"827","article-title":"Gestational diabetes mellitus: major risk factors and pregnancy-related outcomes: a cohort study","volume":"19","author":"Kouhkan","year":"2021","journal-title":"Int J Reprod Biomed"},{"key":"R2-20261106","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"R3-20261106","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R4-20261106","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.cgh.2018.02.024","article-title":"Combining biologics in inflammatory bowel disease and other immune mediated inflammatory disorders","volume":"16","author":"Hirten","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R5-20261106","doi-asserted-by":"crossref","first-page":"7495","DOI":"10.3390\/jcm12237495","article-title":"What should we know about drug levels and therapeutic drug monitoring during pregnancy and breastfeeding in inflammatory bowel disease under biologic therapy?","volume":"12","author":"Barrau","year":"2023","journal-title":"J Clin Med"},{"key":"R6-20261106","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3390\/pharmaceutics14061241","article-title":"The effect of pregnancy and inflammatory bowel disease on the pharmacokinetics of drugs related to inflammatory bowel Disease-A systematic literature review","volume":"14","author":"Wiersma","year":"2022","journal-title":"Pharmaceutics"},{"key":"R7-20261106","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/apt.16102","article-title":"Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure","volume":"52","author":"Flanagan","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"R8-20261106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjac115","article-title":"European Crohn's and Colitis Guidelines on sexuality, fertility, pregnancy, and lactation","volume":"17","author":"Torres","year":"2023","journal-title":"J Crohns Colitis"},{"key":"R9-20261106","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2019.05.067","article-title":"Vedolizumab induces endoscopic and histologic remission in patients with Crohn's Disease","volume":"157","author":"L\u00f6wenberg","year":"2019","journal-title":"Gastroenterology"},{"key":"R10-20261106","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/apt.12030","article-title":"Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays","volume":"36","author":"Vande Casteele","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R11-20261106","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.15484","article-title":"Association between vedolizumab trough concentration and clinical outcomes in inflammatory bowel diseases: a systematic review and meta-analysis","volume":"50","author":"Singh","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R12-20261106","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"R13-20261106","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2016.04.002","article-title":"Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection","volume":"151","author":"Julsgaard","year":"2016","journal-title":"Gastroenterology"},{"issue":"suppl 1","key":"R14-20261106","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/S0140-6736(23)02128-1","article-title":"Autoimmune diseases and adverse pregnancy outcomes: an umbrella review","volume":"402","author":"Singh","year":"2023","journal-title":"Lancet"},{"key":"R15-20261106","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1007\/s10620-015-3677-x","article-title":"Inflammatory bowel disease increases risk of adverse pregnancy outcomes: a meta-analysis","volume":"60","author":"O'Toole","year":"2015","journal-title":"Dig Dis Sci"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:00:45Z","timestamp":1793977245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001519","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"2026-02-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}